Mylan Prepares For US Trastuzumab Entry
Plans To Introduce Herceptin Rival ‘In A Couple Of Weeks’
Mylan is preparing to launch a trastuzumab biosimilar in the US, while progress of developing bevacizumab and aflibercept biosimilars continues. Insulin aspart and glargine are also in Mylan’s pipeline.
